首页 > 医疗资讯/ 正文
Study question
研究问题
Does MOS with LTZ produce higher numbers of goodquality blastocysts compared with the use of clomiphene citrate (CC) for women of an advanced maternal age?
对于高龄女性(AMA),与使用枸橼酸克罗米酚(CC)相比,使用芳香化酶抑制剂来曲唑(LTZ)的卵巢微刺激方案(MOS)是否能产生更多的优质囊胚?
Summary answer
总结答案
MOS using LTZ is a good ovarian stimulation protocol for a higher number of good-quality blastocysts for women of an advanced maternal age (AMA)
对于高龄女性,使用来曲唑的卵巢微刺激方案是一个可以提供更多优质囊胚的方案。
What is known already
已知情况
The clinical pregnancy rate with a good blastocyst should be 40% or more among younger women, but about 35% for AMA women (40 years). Therefore, high-dose gonadotropins are usually used for AMA women. However, the best efforts for both patients and clinicians are sometimes in vain. Many AMA women show a lower ovarian reserve where ovarian stimulation with a lessened dose of gonadotropins is preferred. Taking CC or LTZ with MOS can reduce the amount of gonadotropins used, but it remains uncertain whether it is better to administer LTZ or CC together for MOS.
移植优质囊胚的年轻女性临床妊娠率可达40%或以上,而高龄女性(40岁)仅为35%。因此,对于高龄女性通常使用高剂量的促性腺激素。然而,有时候尽管患者和临床医生都竭尽全力,但收效不佳。许多高龄女性的卵巢储备较低,因此需要使用较低剂量的促性腺激素进行卵巢刺激。在MOS过程中使用克罗米芬或来曲唑可减少促性腺激素的用量,但不能确定在此过程中,使用克罗米芬还是来曲唑,哪个更优。
Study design, size, duration
研究设计,规模,持续时间
This retrospective study was conducted between January 2020 and April 2021. A total of 288 women received MOS. Of course, 153 used CC (CC group) and 133 used LTZ (LTZ group). The ART outcomes were compared between these two groups. Among them, the women who were 40 years old were divided into two groups: CC-O40 (n=61) and LTZ-O40 (n=54). The ART outcomes were compared between the two groups.
这项回顾性研究于2020年1月至2021年4月期间进行。共有288名女性接受卵巢微刺激。当然,153名使用克罗米芬(CC组),133名使用来曲唑(LTZ组)。比较了两组的ART结果。其中,年龄40岁的女性被分为两组CC-O40(n=61)和LTZ-O40(n=54)。比较两组ART的结局。
Participants/materials, setting, methods
参与者/材料,设置,方法
All women took either 100 mg of CC or 5 mg of LTZ daily for 7 days between menstrual cycle 3 (MC3) and MC9, and 225 IU of recombinant-FSH were administered on MC3, MC5, MC7 and MC9. On MC 10, when 3 or more well-developed follicles (20 mm in diameter) were confirmed, a dual-maturation trigger was performed using rec-hCG and GnRH agonist nasal spray, and then oocyte-pick up (OPU) was performed 35-36 hours afterward.
所有女性在月经第3—9天连续7天每日顿服100mg克罗米芬或5mg来曲唑,同时在月经第3、5、7、9天予r-FSH 225 IU。在月经第10天后,当确认有3个或更多发育良好的卵泡(直径 20mm)时,予rec-hCG和GnRH-a鼻喷雾剂进行双扳机,35—36小时后进行取卵(OPU)。
Main results and the role of chance
主要结果和机会的作用
The number of retrieved oocytes in the CC group averaged 7.5±5.3 (mean±S.D.), which was significantly higher than that in the LTZ group (6.3±4.7; p<0.05). The average number of blastocysts and morphologically good blastocysts was comparable in the CC and LTZ groups (CC group; 2.8±3.0 and 1.8±2.4; LTZ group; 2.4±2.7 and 1.4±2.0, respectively, [P=NS]). For AMA women, the average number of blastocysts in the CC-O40 group was 1.7±1.8, which was similar to that in the LTZ-O40 group (1.7±1.8, P=NS). The blastocyst formation rate in the LTZ-O40 group was 58.5%, which was significantly higher than that in the CC-O40 group (46.6%; P<0.05), but the rate for good blastocysts in the LTZ-O40 group (30.8%) was comparable to that in the CC-O40 group (23.3%, P=NS). The euploid rates in the LTZ group was 53.4%, which was significantly higher than that in the CC group (38.0%;P<0.05), and the difference was significant even for AMA women (LTZO40; 40.5%, CC-O40; 16.7%, respectively, p< 0.05).
CC组中平均获卵数为7.5±5.3(平均数±标准差),显著高于LTZ组(6.3±4.7;P<0.05)。CC组和LTZ组平均囊胚数和形态良好的囊胚数相似,分别为(2.8±3.0和1.8±2.4)和(2.4±2.7和1.4±2.0)(P=NS)。对于高龄女性,CC-O40组的平均囊胚数为1.7±1.8,与LTZ-O40组相似(1.7±1.8,P=NS)。LTZ-O40组囊胚形成率明显高于CC-O40组(58.5% vs 46.6%,P<0.05);但LTZ-O40组的优质囊胚形成率与CC-O40组相似(30.8% vs 23.3%,P=NS)。LTZ组的整倍体率显著高于CC组(53.4% vs 38.0%,P<0.05);即使在高龄女性中也有显著差异(LTZ-O40 vs CC-O40,40.5% vs 16.7%,P<0.05)。
Limitations, reasons for caution
局限性,谨慎的理由
The study was a controlled trial with a limited number in the study population. Additionally, all cases had not received a trophectoderm (TE) biopsy. Further study is needed to determine the effect that an aromatase inhibitor exerts on obtaining either morphologically good blastocysts or euploid blastocysts.
本研究是一项研究人群数量有限的对照试验。此外,所有病例均未进行滋养外胚层(TE)活检。需要进一步的研究来确定芳香化酶抑制剂对获得形态良好的囊胚或整倍体囊胚的影响。
Wider implications of the findings
研究结果更广泛的含义
AMA women showed blastocyst formation rates from LTZ with MOS significantly higher than that of the CC group, and euploid rates in the LTZ group were also significantly higher. The characteristics of an LTZ such as aromatase inhibitor enhanced the development of embryos.
高龄女性采用LTZ+MOS囊胚形成率和整倍体率均显著高于CC+MOS。LTZ等芳香化酶抑制剂的特性促进了胚胎的发育。
参考文献:
T Horikawa, K Nakagawa, K Shiobara, K Kuroda, T Maruyama, S Takamizawa, R Sugiyama, P-586 Mild ovarian stimulation using the aromatase inhibitor letrozole (LTZ) is an effective stimulation protocol to obtain euploid blastocysts for women of an advanced maternal age, Human Reproduction, Volume 39, Issue Supplement_1, July 2024, deae108.183, https://doi.org/10.1093/humrep/deae108.183
- 搜索
-
- 1000℃Cell | 曾泽贤/潘登/冯驭团队开发SPAC-seq新技术,实现空间分辨率下高通量CRISPR筛选
- 1000℃福建师范大学ACS Nano:人工智能驱动的Janus敷料用于可视化伤口诊疗
- 1000℃中科院苏州纳米所ACS Nano综述:通过可穿戴AI接口学习人类-环境交互
- 1000℃Cancer Discov | 新型AI基础模型可根据基因型精准预测癌症治疗反应,涵盖10种实体瘤超3万个肿瘤基因组数据
- 1000℃新加坡国立大学/复旦大学《自然·通讯》:抗氧化脂质纳米颗粒增强mRNA稳定性用于再生治疗和基因编辑
- 1000℃489例疑似罕见遗传病患者进行全外显子测序WES:确诊率达53%,5.5%检出心血管或肿瘤相关基因变异
- 1000℃Nat Cancer | 基于组织病理学图像的AI模型可快速识别102种CNS肿瘤亚型,表现优于神经病理学家
- 1000℃国立清华大学《自然·通讯》:工程化人类PEG10纳米颗粒实现RNA自包装、递送与癌症治疗
- 精J Child Psychol Psychiatry:12种罕见神经发育障碍儿童沟通能力谱系
- 精研究发现:爱吃辣的人,心血管病和癌症死亡风险都会显著降低
- 精Nursing in Critical Care:别再指责护士了!ICU 里被遗漏的护理,根源在系统而非个人
- 精Acta Obstet Gynecol Scand:罕见病女性的妊娠并发症与母婴结局,一项单中心434种罕见病的回顾性队列研究
- 精【爱儿小醉】儿科患者术前对流层臭氧暴露与围手术期呼吸系统不良事件之间的关系:一项单中心回顾性队列研究
- 精eBioMedicine:牙龈下微生物组与脑健康存在连续关联梯度,牙周炎或成认知衰退可干预靶点
- 精军事医学研究院《自然·通讯》:自适应IrPtCu纳米酶水凝胶实现耐药菌感染伤口序贯治疗
- 精能够逆转萎缩性胃炎的两个中成药,该怎么选择?
- 荐Lancet子刊:国产CRVIAAI精准识别胰腺癌血管侵犯,准确率超越资深影像专家
- 荐Pharmacol Res:胃癌耐药的 "双重密码",细胞因子与表观遗传的异常对话
- 荐新一代ICU体系:德尔格持续升级整体解决方案能力,实现更智能、安静、高效的诊疗环境!
- 荐论文解读│经由多组学视角更新法布雷病重要靶器官病理生理机制
- 荐【醉翁之艺】小胶质细胞激活通过CXCL10介导的CD8+T细胞募集促进衰老相关白质退化
- 荐《柳叶刀》重磅:奥瑞珠单抗显著延缓原发进展型多发性硬化老年及重度残疾患者进展
- 荐STTT:派安普利单抗联合化疗为复发转移性鼻咽癌带来持久生存获益
- 荐ASCO 2026:中国领衔LIBRETTO-432研究,塞普替尼引领RET融合阳性非小细胞肺癌早期治疗新突破,降低83%的疾病复发或死亡风险
- 标签列表
-
- 星座 (702)
- 孩子 (526)
- 恋爱 (505)
- 婴儿车 (390)
- 宝宝 (328)
- 狮子座 (313)
- 金牛座 (313)
- 摩羯座 (302)
- 白羊座 (301)
- 天蝎座 (294)
- 巨蟹座 (289)
- 双子座 (289)
- 处女座 (285)
- 天秤座 (276)
- 双鱼座 (268)
- 婴儿 (265)
- 水瓶座 (260)
- 射手座 (239)
- 不完美妈妈 (173)
- 跳槽那些事儿 (168)
- baby (140)
- 女婴 (132)
- 生肖 (129)
- 女儿 (129)
- 民警 (127)
- 狮子 (105)
- NBA (101)
- 家长 (97)
- 怀孕 (95)
- 儿童 (93)
- 交警 (89)
- 孕妇 (77)
- 儿子 (75)
- Angelababy (74)
- 父母 (74)
- 幼儿园 (73)
- 医院 (69)
- 童车 (66)
- 女子 (60)
- 郑州 (58)